Bryan Cox
Hoofd Techniek/Wetenschap/O&O bij TRISALUS LIFE SCIENCES, INC.
Vermogen: 860 891 $ op 30-04-2024
Actieve functies van Bryan Cox
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 10-08-2023 | - |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Algemeen Directeur | 01-11-2018 | - |
Loopbaan van Bryan Cox
Eerdere bekende functies van Bryan Cox
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01-01-1996 | 01-01-2013 |
Opleiding van Bryan Cox
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
| University of Iowa | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics, Inc. is a biopharmaceutical company that focuses on developing a family of proprietary drug candidates to prevent and treat acute kidney injury (AKI). The company is based in Lake Forest, IL. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The CEO of the company is Bryan F. Cox. | Health Technology |
